Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
BTCY

BTCY - Biotricity Inc. Stock Price, Fair Value and News

0.94USD+0.03 (+3.30%)Delayed as of 13 Jun 2024, 09:48 am ET

Market Summary

BTCY
USD0.94+0.03
Delayedas of 13 Jun 2024, 09:48 am
3.30%

BTCY Stock Price

View Fullscreen

BTCY RSI Chart

BTCY Valuation

Market Cap

8.4M

Price/Earnings (Trailing)

-0.58

Price/Sales (Trailing)

0.72

EV/EBITDA

-0.71

Price/Free Cashflow

-1.14

BTCY Price/Sales (Trailing)

BTCY Profitability

Operating Margin

65.52%

EBT Margin

-125.43%

Return on Equity

-15.62%

Return on Assets

-265.83%

Free Cashflow Yield

-87.9%

BTCY Fundamentals

BTCY Revenue

Revenue (TTM)

11.6M

Rev. Growth (Yr)

20.89%

Rev. Growth (Qtr)

2.82%

BTCY Earnings

Earnings (TTM)

-14.6M

Earnings Growth (Yr)

37.83%

Earnings Growth (Qtr)

23.92%

Breaking Down BTCY Revenue

52 Week Range

0.94
(Low)(High)

Last 7 days

-8.9%

Last 30 days

-15.6%

Last 90 days

-24.6%

Trailing 12 Months

-77.8%

How does BTCY drawdown profile look like?

BTCY Financial Health

Current Ratio

0.21

BTCY Investor Care

Shares Dilution (1Y)

8.83%

Diluted EPS (TTM)

0.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20239.6M10.6M11.1M11.6M
20227.7M7.9M8.5M9.0M
20213.4M4.7M5.8M6.7M
20201.4M1.5M1.9M2.6M
2019414.6K724.0K952.2K1.2M
20180000

Tracking the Latest Insider Buys and Sells of Biotricity Inc.

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Nov 29, 2021
rosa david a
acquired
-
-
27,174
-
Nov 29, 2021
betts norman m.
acquired
-
-
54,348
-
Oct 11, 2021
rosa david a
sold
-10,119
3.05
-3,318
-
Oct 08, 2021
rosa david a
sold
-30,333
3.1994
-9,481
-
Oct 07, 2021
rosa david a
sold
-53,119
3.0833
-17,228
-
Sep 16, 2021
rosa david a
sold
-119,915
3.4284
-34,977
-
Sep 15, 2021
rosa david a
sold
-20,421
3.2695
-6,246
-
Apr 07, 2020
kennedy patricia j
acquired
-
-
125,000
-
Apr 07, 2020
betts norman m.
acquired
-
-
125,000
-

1–9 of 9

Which funds bought or sold BTCY recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jun 11, 2024
EverSource Wealth Advisors, LLC
new
-
31.00
31.00
-%
May 15, 2024
STATE STREET CORP
unchanged
-
6,764
33,371
-%
May 15, 2024
MORGAN STANLEY
unchanged
-
23.00
105
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-114
-
-%
May 15, 2024
AE Wealth Management LLC
sold off
-100
-36,640
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
reduced
-73.01
-4,238
2,256
-%
May 15, 2024
Royal Bank of Canada
unchanged
-
-
1,000
-%
May 14, 2024
NORTHERN TRUST CORP
unchanged
-
3,961
17,763
-%
May 13, 2024
HRT FINANCIAL LP
sold off
-100
-22,000
-
-%
May 13, 2024
FMR LLC
sold off
-100
-20.00
-
-%

1–10 of 24

Are Funds Buying or Selling BTCY?

Are funds buying BTCY calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own BTCY
No. of Funds

Recent SEC filings of Biotricity Inc.

View All Filings
Date Filed Form Type Document
Jun 07, 2024
8-K
Current Report
May 28, 2024
424B3
Prospectus Filed
May 28, 2024
8-K
Current Report
May 21, 2024
8-K
Current Report
May 16, 2024
424B3
Prospectus Filed
May 15, 2024
EFFECT
EFFECT
May 15, 2024
EFFECT
EFFECT
May 15, 2024
S-3/A
S-3/A
May 09, 2024
S-3
S-3
May 08, 2024
S-3
S-3

Peers (Alternatives to Biotricity Inc.)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
181.6B
40.3B
-0.37% 2.47%
32.26
4.5
-2.84% -3.00%
67.6B
19.7B
-1.25% -6.96%
50.73
3.43
4.82% -17.56%
20.0B
3.9B
-2.42% -17.36%
43.34
5.12
5.72% 46.72%
17.0B
14.9B
-5.98% -23.37%
6.41
1.14
2.98% 207.68%
MID-CAP
9.7B
3.5B
-1.37% 26.59%
30.89
2.73
6.16% 35.06%
8.5B
12.4B
-9.19% -12.63%
21.92
0.69
-0.93% -18.83%
8.1B
2.6B
-0.75% -24.43%
-25.06
3.1
-6.25% -68.58%
5.6B
3.9B
-4.01% -30.77%
-58.81
1.43
0.23% 90.80%
3.4B
387.1M
-0.49% 33.89%
-214.54
8.83
30.82% 65.57%
2.0B
6.6B
-10.56% -17.38%
10.58
0.31
2.78% -0.87%
SMALL-CAP
1.5B
3.2B
21.26% 13.50%
-2.2
0.47
7.94% -1695.32%
387.0M
169.3M
2.11% -4.54%
-5.04
2.29
7.49% -244.90%
245.9M
324.0M
0.33% -43.67%
-1.28
0.76
-3.19% -337.41%
53.7M
50.5M
8.39% -77.60%
-2.35
1.06
14.25% -10.06%
1.4M
3.7M
-47.47% -84.71%
-0.11
0.36
5.77% 8.23%

Biotricity Inc. News

Latest updates
Investing.com Nigeria18 Apr 202407:00 am

Biotricity Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue2.8%2,972,9722,891,2973,020,7652,742,4352,459,1812,381,3892,056,0522,148,7421,930,1081,807,3091,764,1101,187,0331,001,252744,585451,898362,920381,899345,906327,000161,700117,640
Cost Of Revenue-9.8%804,986892,0191,104,0611,207,7341,057,2151,101,152830,923708,1051,105,271672,711594,029455,173859,363609,296201,342585,617100,782114,216150,586-27,504
Gross Profit8.4%2,167,9861,999,2781,916,7041,534,7011,401,9661,280,2371,225,1291,440,637824,8371,134,5981,170,081731,860141,889135,289250,556-222,697281,117231,690176,414-106,92090,136
Operating Expenses-17.6%3,449,7604,184,9514,233,1904,988,3065,240,4245,309,2245,313,7915,270,7985,560,1376,303,4244,172,5973,978,0214,019,7932,994,3383,619,2364,263,8222,627,5672,239,8042,266,0151,717,8872,262,384
  S&GA Expenses-14.1%2,996,8043,487,3313,520,2154,284,9774,363,9644,480,3104,492,6154,641,3454,659,6385,677,7863,583,6003,426,5253,338,3822,591,9983,195,3533,780,2482,179,9282,021,2792,052,5191,409,5031,861,113
  R&D Expenses-35.1%452,956697,620712,975703,329876,460828,914821,176629,453900,499625,638588,997551,496681,411402,340423,883483,575447,639218,525213,496308,384401,271
EBITDA Margin18.8%-1.01-1.24-1.43-1.74-2.02-2.45-3.40-3.64-3.93-4.01-3.26-3.78-5.54--------
Interest Expenses4.9%790,080753,268660,512633,818413,402403,551388,388---------400-----
Earnings Before Taxes23.9%-2,808,091-3,690,840-3,412,882-4,672,228-4,517,115-4,692,548-4,776,252-5,611,839-7,109,649-10,752,890-5,656,099-5,471,544-3,900,245-2,962,207-3,157,179-4,598,222-2,371,005-2,008,114-2,089,601-1,824,806-2,172,248
EBT Margin14.4%-1.25-1.47-1.63-1.94-2.17-2.61-3.56-3.81-4.33-4.48-3.83-4.58-5.71--------
Net Income23.9%-2,808,091-3,690,840-3,412,882-4,672,228-4,517,115-4,692,548-4,776,252-5,611,839-7,109,649-10,752,890-5,656,099-5,374,936-3,900,245-3,155,424-3,157,179-4,598,222-2,371,005-2,008,114-2,089,601-1,824,806-2,172,248
Net Income Margin14.4%-1.25-1.47-1.63-1.94-2.17-2.61-3.56-3.81-4.32-4.46-3.85-4.61-5.78--------
Free Cashflow45.4%-1,305,966-2,390,036-1,832,118-1,878,268-3,179,465-4,450,810-4,039,395-4,755,102-4,497,584------------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Assets-19.6%5,4866,8246,1446,5116,6478,05312,15016,67821,04513,9522,7674,4385,1402,0681,3892,0045,5291,0581,047491473
  Current Assets-24.1%3,9325,1784,4014,7204,7946,75210,84715,32319,61013,9462,7454,3224,9421,8281,1241,6595,182661601458440
    Cash Equivalents-92.9%85.001,20051.005704512,4987,20812,06716,79011,6942022,2023,32447065.009504,35443.0048.0064.0026.00
  Inventory-3.7%2,0492,1282,2162,3371,9321,8541,43184336011818027295.0017923686.0098.0033.0040.0025.00126
  Net PPE-8.0%17.0019.0020.0022.0023.0024.0026.0027.0029.00------------
Liabilities-0.3%32,21432,29529,55626,35622,12918,67718,71018,82318,7266,20713,36711,27115,8479,4816,3745,0057,4425,9564,3122,2681,324
  Current Liabilities4.5%18,61917,82415,09811,1617,2914,3894,5774,8674,8295,21512,29010,4908,4437,1063,8213,8036,5385,7894,0922,268-
Shareholder's Equity---------2,3197,745-----------
  Retained Earnings-2.5%-123,100-120,100-116,172-112,570-107,713-102,965-98,061-93,037-87,055-79,712-68,715-62,817-57,033-52,914-49,758-46,364-41,531-39,137-37,129-35,039-33,216
  Additional Paid-In Capital2.4%95,56193,33893,01292,84492,29792,33591,91391,50785,87430857,19256,29930823045,67744,01540,54734,99334,29633,89032,595
Shares Outstanding8.1%9,2598,56651,0488,5088,6368,64351,44149,8107,2916,8376,5166,0216,173--------
Float------32,626---114,850---31,498---14,261---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Cashflow From Operations45.4%-1,305-2,390-1,832-1,878-3,179-4,450-4,039-4,755-4,487-3,239-2,681-3,579-2,971-2,136-2,393-2,952-2,118-1,462-1,328-1,157-1,392
  Share Based Compensation4.2%17016321128263.0015314948710117015631114.002302331,689155155339351373
Cashflow From Investing---------1*-------------
Cashflow From Financing-94.3%1953,4291,3291,9971,110-272-8331559,61914,8135812,5865,4392,6041,574-5856,6611,4741,3301,5281,238
  Dividend Payments---------39716620532.00295--------
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

BTCY Income Statement

2023-12-31
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended9 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Dec. 31, 2023
Dec. 31, 2022
Income Statement [Abstract]    
REVENUE$ 2,972,972$ 2,459,181$ 8,885,034$ 6,896,622
Cost of Revenue804,9861,057,2152,801,0662,989,290
NET REVENUE2,167,9861,401,9666,083,9683,907,332
EXPENSES    
Selling. general and administrative expenses2,996,8044,363,96410,004,35013,336,888
Research and development expenses452,956876,4601,863,5512,526,550
TOTAL OPERATING EXPENSES3,449,7605,240,42411,867,90115,863,438
LOSS FROM OPERATIONS(1,281,774)(3,838,458)(5,783,933)(11,956,106)
Interest expense [Note 5, 6 and 9](790,080)(413,402)(2,203,860)(1,205,342)
Accretion and amortization expenses [Note 5,6](422,706)(51,061)(1,576,345)(151,970)
Change in fair value of derivative liabilities [Note 8](326,683)(99,705)(244,014)(469,971)
Gain (loss) upon convertible promissory notes conversion and redemption2,1485,39115,280(85,537)
Other (expense) income [Note 13]11,004(119,880)(118,941)(116,989)
NET LOSS BEFORE INCOME TAXES(2,808,091)(4,517,115)(9,911,813)(13,985,915)
Income taxes
NET LOSS BEFORE DIVIDENDS(2,808,091)(4,517,115)(9,911,813)(13,985,915)
Adjustment: Preferred Stock Dividends(237,904)(230,374)(617,043)(690,330)
NET LOSS ATTRIBUTABLE TO COMMON STOCKLHOLDERS(3,045,995)(4,747,489)(10,528,856)(14,676,245)
Translation adjustment(204,501)(72,823)(99,091)625,698
COMPREHENSIVE LOSS$ (3,250,496)$ (4,820,312)$ (10,627,947)$ (14,050,547)
LOSS PER SHARE, BASIC$ (0.339)$ (0.546)$ (1.191)$ (1.699)
LOSS PER SHARE, DILUTED$ (0.339)$ (0.546)$ (1.191)$ (1.699)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - BASIC8,979,4308,690,5068,842,8908,635,900
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - DILUTED8,979,4308,690,5068,842,8908,635,900

BTCY Balance Sheet

2023-12-31
Condensed Consolidated Balance Sheets - USD ($)
Dec. 31, 2023
Mar. 31, 2023
CURRENT ASSETS  
Cash$ 85,094$ 570,460
Accounts receivable, net1,573,5831,224,137
Inventories [Note 3]2,048,9102,337,006
Deposits and other receivables224,895588,599
Total current assets3,932,4824,720,202
Deposits [Note 10]85,00085,000
Long-term accounts receivable135,56096,344
Property and equipment [Note 12]17,04121,506
Operating right of use assets [Note 10]1,316,1351,587,492
TOTAL ASSETS5,486,2186,510,544
CURRENT LIABILITIES  
Accounts payable and accrued liabilities [Note 4]7,558,7455,042,476
Convertible promissory notes and short term loans [Note 5]7,922,0974,774,468
Term loan, current [Note 6]1,800,000
Derivative liabilities [Note 8]928,3331,008,216
Operating lease obligations, current [Note 10]409,702335,608
Total current liabilities18,618,87711,160,768
Federally guaranteed loans [Note 7]870,800870,800
Term loan [Note 6]10,533,42512,178,809
Derivative liabilities [Note 8]1,139,293759,065
Operating lease obligations [Note 10]1,051,3211,386,487
TOTAL LIABILITIES32,213,71626,355,929
STOCKHOLDERS’ DEFICIENCY  
Common stock, $0.001 par value, 125,000,000 shares authorized as of December 31, 2023 and March 31, 2023. Issued and outstanding common shares: 9,258,957 and 8,508,052 as of December 31, 2023 and March 31, 2023, respectively, and exchangeable shares of 160,672 and 244,458 outstanding as at December 31, 2023 and March 31, 2023, respectively [Note 9]9,4208,753
Shares to be issued, 3,955 shares of common stock as of December 31, 2023 and March 31, 2023 [Note 9]24,99924,999
Additional paid-in-capital95,560,78992,844,478
Accumulated other comprehensive income/(loss)(251,888)(152,797)
Accumulated deficit(123,099,681)(112,570,825)
TOTAL STOCKHOLDERS’ DEFICIENCY(27,756,354)(19,845,385)
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ DEFICIENCY5,486,2186,510,544
Serie B Convertible Redeemable Preferred Stock [Member]  
Mezzanine Equity  
Series B Convertible Redeemable preferred stock, $0.001 par value, 600 and no shares authorized as of December 31, 2023 and March 31, 2023, respectively, 220 and no shares issued and outstanding as of December 31, 2023 and March 31, 2023, respectively [Note 9]1,028,856
Preferred Stock [Member]  
STOCKHOLDERS’ DEFICIENCY  
Preferred stock, value11
Series A Preferred Stock [Member]  
STOCKHOLDERS’ DEFICIENCY  
Preferred stock, value$ 6$ 6
BTCY
Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.
 CEO
 WEBSITEbiotricity.com
 INDUSTRYMedical Instruments & Supplies
 EMPLOYEES55

Biotricity Inc. Frequently Asked Questions


What is the ticker symbol for Biotricity Inc.? What does BTCY stand for in stocks?

BTCY is the stock ticker symbol of Biotricity Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Biotricity Inc. (BTCY)?

As of Wed Jun 12 2024, market cap of Biotricity Inc. is 8.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of BTCY stock?

You can check BTCY's fair value in chart for subscribers.

What is the fair value of BTCY stock?

You can check BTCY's fair value in chart for subscribers. The fair value of Biotricity Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Biotricity Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for BTCY so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Biotricity Inc. a good stock to buy?

The fair value guage provides a quick view whether BTCY is over valued or under valued. Whether Biotricity Inc. is cheap or expensive depends on the assumptions which impact Biotricity Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BTCY.

What is Biotricity Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Jun 12 2024, BTCY's PE ratio (Price to Earnings) is -0.58 and Price to Sales (PS) ratio is 0.72. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BTCY PE ratio will change depending on the future growth rate expectations of investors.